AU2012282825B2 - Method for detection of amyloid beta oligomers in a fluid sample and uses thereof - Google Patents

Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Download PDF

Info

Publication number
AU2012282825B2
AU2012282825B2 AU2012282825A AU2012282825A AU2012282825B2 AU 2012282825 B2 AU2012282825 B2 AU 2012282825B2 AU 2012282825 A AU2012282825 A AU 2012282825A AU 2012282825 A AU2012282825 A AU 2012282825A AU 2012282825 B2 AU2012282825 B2 AU 2012282825B2
Authority
AU
Australia
Prior art keywords
antibody
oligomer
ndpoi
oligomers
bead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012282825A
Other languages
English (en)
Other versions
AU2012282825A1 (en
Inventor
Alexander Mccampbell
Mary SAVAGE
Paul Shughrue
Abigail WOLFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2012282825A1 publication Critical patent/AU2012282825A1/en
Application granted granted Critical
Publication of AU2012282825B2 publication Critical patent/AU2012282825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AU2012282825A 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Active AU2012282825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
AU2012282825A1 AU2012282825A1 (en) 2014-01-16
AU2012282825B2 true AU2012282825B2 (en) 2016-05-26

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012282825A Active AU2012282825B2 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732286A4 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3449926T3 (da) 2009-06-17 2019-11-11 Biogen Ma Inc Sammensætninger og fremgangsmåder til modulering af smn2-splejsning hos et individ
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
AU2014352944A1 (en) * 2013-11-20 2016-06-16 The General Hospital Corporation Methods and compositions for treating amyloid deposits
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
WO2017033152A1 (en) * 2015-08-25 2017-03-02 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
JP6320651B2 (ja) 2016-02-08 2018-05-09 シスメックス株式会社 被検物質の検出方法および被検物質の検出用試薬キット
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
JP7299566B2 (ja) * 2019-07-05 2023-06-28 株式会社島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
KR20220148230A (ko) 2020-02-28 2022-11-04 아이오니스 파마수티컬즈, 인코포레이티드 Smn2를 조절하기 위한 화합물 및 방법
KR102798206B1 (ko) * 2021-06-25 2025-04-22 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
ATE445639T1 (de) 1999-08-04 2009-10-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
AU2005231364A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
EP2465872A3 (en) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
RU2008120027A (ru) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
EP2576617B1 (en) * 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
ES2573135T3 (es) * 2010-07-14 2016-06-06 Merck Sharp & Dohme Corp. Anticuerpo monoclonal anti-ADDL y usos del mismo
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D1 : US 2011/0166035 A1 (KLEINSCHMIDT ET AL) 07 July 2011 *
D2 : SANTOS ET AL:Journal of Alzheimer's disease, 2008, vol. 14, pages 127-131 *
D3 : PESARESI ET AL: "Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment". Neurobiology of Aging, 2006, vol. 27, pages 904-905 *

Also Published As

Publication number Publication date
EP2732286A1 (en) 2014-05-21
AU2012282825A1 (en) 2014-01-16
WO2013009667A1 (en) 2013-01-17
CN103782171A (zh) 2014-05-07
RU2014105172A (ru) 2015-08-20
EP2732289B1 (en) 2018-04-11
CA2840976A1 (en) 2013-01-17
KR20140072019A (ko) 2014-06-12
JP2014521089A (ja) 2014-08-25
EP2732286A4 (en) 2015-02-25
WO2013009703A3 (en) 2013-03-21
DK2732289T3 (en) 2018-05-22
BR112014000671A2 (pt) 2017-02-14
WO2013009703A2 (en) 2013-01-17
ES2666840T3 (es) 2018-05-08
EP2732289A2 (en) 2014-05-21
MX2014000480A (es) 2014-06-23
WO2013009703A8 (en) 2014-01-23
US20140120037A1 (en) 2014-05-01
US20130052670A1 (en) 2013-02-28
CN103782171B (zh) 2016-12-14

Similar Documents

Publication Publication Date Title
AU2012282825B2 (en) Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
AU2005306997B2 (en) Anti-ADDL antibodies and uses thereof
US20150023952A1 (en) Anti-addl monoclonal antibody and uses thereof
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
AU2011204912B2 (en) Anti-ADDL antibodies and uses thereof
WO2025260029A1 (en) Method for quantifying amyloid beta protofibril
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
TW202344840A (zh) 診斷檢定
WO2025137532A1 (en) Method for quantifying amyloid beta protofibril
AU2012232964B2 (en) Anti-ADDL antibodies and uses thereof
WO2013115348A1 (ja) ｓＡＰＰβに対する抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)